| Recruitment status | No longer recruiting |
| Unique ID issued by UMIN | UMIN000031265 |
| Receipt No. | R000035347 |
| Official scientific title of the study | Pre-examination: A confirmatory test for efficacy to skin of the rich nobiletin extract from Shikuwasa. |
| Date of disclosure of the study information | 2019/02/15 |
| Last modified on | 2018/06/13 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Pre-examination: A confirmatory test for efficacy to skin of the rich nobiletin extract from Shikuwasa. | |
| Title of the study (Brief title) | Pre-examination: Evaluation of natural beauty ingredient for skin | |
| Region |
|
|
| Condition | |||
| Condition | Because it is a test for healthy subjects, there is no target disease. | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | Shikuwasa (scientific name: Citrus depressa) is a plant native to Okinawa since ancient times and contains a lot of "nobiletin" which is one kind of flavonoids. Nobiletin prevents skin damage due to ultraviolet rays, suppresses the formation of melanin pigment, and suppresses skin inflammatioShikuwasa (scientific name: Citrus depressa) is a plant native to Okinawa since ancient times and contains a lot of "nobiletin" which is one kind of flavonoids. Nobiletin prevents skin damage due to ultraviolet rays, suppresses the formation of melanin pigment, and suppresses skin inflammation caused by ultraviolet rays. However, there are few research reports on the efficacy of the Shikuwasa extract to the skin. This study was planned for the purpose of preliminary examination with a small number of examinees in order to confirm the usefulness to the skin using Shikuwasa extract . |
| Basic objectives2 | Others |
| Basic objectives -Others | usefulness |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Skin measurement
1.Stain / wrinkle measurement with Robo SkinAnalyzer 2.Skin viscoelasticity, water content, oil content |
| Key secondary outcomes | Result of the questionnaire survey |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Application of lotion containing nobiletin to skin | |
| Interventions/Control_2 | Application of a lotion to the skin | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | 1. Healthy people who do not have severe disease (diabetes, heart disease, liver disease, kidney disease, cancer, etc.)
2. Women who suffer from skin weakness, spots and wrinkles 3. A person who wishes to voluntarily participate in the clinical trial from the age of 40 to 70 and obtain written consent 4. Those who have not changed the basic cosmetics or cosmetics within the first month before the start of the test and those who can not change during the test period 5. The use of basic cosmetics during the examination period can be used only for the test item 6. Persons who do not constantly consume health food or the like considered to have an effect on the skin within one month before commencement of testing 7. Those who have not received any special skin care treatment during the examination from 1 month before the examination 8. Those who can avoid drastic changes in UV exposure such as swimming, mountain climbing, sunbathing, outdoor exercise compared to before the test 9. Persons who can keep constant daily lifestyle during the examination period 10. Study participation of people who are treating mild chronic diseases (hypertension, hyperlipemia, etc.) shall be able to participate at the discretion of the investigator |
|||
| Key exclusion criteria | 1. People with severe diseases (diabetes, heart disease, liver disease, kidney disease, cancer, etc.) and mental disorders
2. One who ingests internal or external medicine for atopic dermatitis, skin diseases such as urticaria, etc, regularly or within 1 month taking 1/3 of the month or more 3. People with skin conditions and skin diseases that may have an impact on the test 4. Cosmetics containing seekers, those who have experienced allergic symptoms in food, people with drug allergy 5. Pregnant women / lactating women and those who wish pregnancy during the examination period 6. Other persons who did not qualify for participation in the exam by the investigator 7. If you are participating in other clinical trials within the past month |
|||
| Target sample size | 26 | |||
| Research contact person | |
| Name of lead principal investigator | Nishiyama, Masaki |
| Organization | Wellbe Inc. |
| Division name | Clinical Research Division |
| Address | Tanahara BLDG 3F, 1-3-2 Nishihara, Urasoe, Okinawa, Japan |
| TEL | 098-988-9007 |
| abe@well-b.jp | |
| Public contact | |
| Name of contact person | Abe, Hiroyuki |
| Organization | Wellbe Inc. |
| Division name | Clinical Research Division |
| Address | Tanahara BLDG 3F, 1-3-2 Nishihara, Urasoe, Okinawa, Japan |
| TEL | 098-988-9007 |
| Homepage URL | |
| abe@well-b.jp | |
| Sponsor | |
| Institute | Wellbe Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Okinawa Prefecture |
| Organization | |
| Division | |
| Category of Funding Organization | Local Government |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | No longer recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035347 |